FCX vs ZYME · P/E 38, rev $25.45B vs rev $76.3M
Freeport-McMoran Copper & Gold Inc (FCX) versus Zymeworks Inc. Common Stock (ZYME) — a side-by-side from cached financials, not a winner call.
Freeport-McMoran Copper & Gold Inc (FCX) is a copper company listed on US.
Zymeworks Inc. Common Stock (ZYME) is a biotechnology company listed on NASDAQ.
Latest reported FCX revenue for 2024-12-31 was $25.45B. Net income was $4.40B. Revenue was up 11.4% from 2023-12-31 to 2024-12-31. FCX currently screens at market cap $67.80B and trailing P/E 38.0.
Latest reported ZYME revenue for 2024-12-31 was $76.3M. Net income was -$122.7M. Revenue was up 0.4% from 2023-12-31 to 2024-12-31. ZYME currently screens at market cap $1.68B.
FCX currently screens at market cap $67.80B and trailing P/E 38.0. ZYME currently screens at market cap $1.68B.
Not investment advice. Open the FCX and ZYME stock pages for the full models.
Not investment advice.